Last reviewed · How we verify
IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial
The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
Details
| Lead sponsor | Baylor Research Institute |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | 2011-01 |
| Completion | 2016-12 |
Conditions
- Malignant Melanoma Stage III
- Malignant Melanoma Stage IV
Interventions
- IL15-DC Vaccine
Primary outcomes
- Immune response — 14 weeks
Countries
United States